Equities Analysts Set Expectations for Nkarta Q3 Earnings

Key Points

• HC Wainwright lowered Nkarta’s Q3 2026 EPS estimate to a loss of $0.46 per share from $0.41, while maintaining a “Buy” rating and a $14 price target.
• Nkarta reported a Q2 loss of $0.54 per share, missing the consensus estimate of a $0.36 loss by $0.18. Analysts collectively rate the stock “Moderate Buy,” with a consensus price target of $11.40.
• NKTX shares opened at $2.39, with a market capitalization of about $171 million; institutional investors own 80.54% of the company, including a new $17.8 million BlackRock stake.

Nkarta, Inc. (NASDAQ:NKTX - Free Report) - HC Wainwright decreased their Q3 2026 earnings per share (EPS) estimates for shares of Nkarta in a report released on Tuesday, August 11th. HC Wainwright analyst E. Bodnar now anticipates that the company will post earnings per share of ($0.46) for the quarter, down from their previous forecast of ($0.41). HC Wainwright has a "Buy" rating and a $14.00 price objective on the stock. The consensus estimate for Nkarta's current full-year earnings is ($1.43) per share. HC Wainwright also issued estimates for Nkarta's Q4 2026 earnings at ($0.48) EPS, FY2026 earnings at ($1.86) EPS, FY2027 earnings at ($2.26) EPS, FY2028 earnings at ($1.76) EPS, FY2029 earnings at ($1.53) EPS and FY2030 earnings at ($1.23) EPS.

NKTX has been the topic of several other reports. Weiss Ratings restated a "sell (d-)" rating on shares of Nkarta in a research report on Wednesday, June 24th. Evercore set a $9.00 target price on Nkarta in a research report on Monday, May 18th. TD Cowen began coverage on shares of Nkarta in a report on Tuesday, June 23rd. They set a "buy" rating on the stock. Wall Street Zen raised shares of Nkarta from a "strong sell" rating to a "sell" rating in a research report on Sunday, August 2nd. Finally, Needham & Company LLC reaffirmed a "buy" rating and issued a $11.00 price objective on shares of Nkarta in a report on Wednesday, May 13th. One equities research analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating and one has given a Sell rating to the company's stock. Based on data from MarketBeat.com, the company has an average rating of "Moderate Buy" and a consensus target price of $11.40.

Nkarta Stock Up 2.6%

NKTX opened at $2.39 on Thursday. The business's fifty day simple moving average is $2.65 and its 200 day simple moving average is $2.58. Nkarta has a 52 week low of $1.70 and a 52 week high of $3.72. The stock has a market cap of $170.98 million, a PE ratio of -1.52 and a beta of 0.93.

Nkarta (NASDAQ:NKTX - Get Free Report) last released its quarterly earnings results on Monday, August 10th. The company reported ($0.54) earnings per share for the quarter, missing the consensus estimate of ($0.36) by ($0.18).

Institutional Trading of Nkarta

Several hedge funds have recently bought and sold shares of NKTX. BlackRock Inc. purchased a new stake in shares of Nkarta during the 2nd quarter valued at about $17,830,000. GSK plc purchased a new stake in Nkarta during the fourth quarter valued at approximately $5,829,000. Monaco Asset Management SAM lifted its stake in shares of Nkarta by 29.2% in the 4th quarter. Monaco Asset Management SAM now owns 2,546,932 shares of the company's stock valued at $4,712,000 after purchasing an additional 576,022 shares during the last quarter. Renaissance Technologies LLC boosted its holdings in shares of Nkarta by 1.8% in the 1st quarter. Renaissance Technologies LLC now owns 1,732,372 shares of the company's stock worth $3,655,000 after purchasing an additional 30,350 shares during the period. Finally, Geode Capital Management LLC boosted its holdings in shares of Nkarta by 0.8% in the 2nd quarter. Geode Capital Management LLC now owns 1,208,378 shares of the company's stock worth $2,006,000 after purchasing an additional 10,065 shares during the period. Hedge funds and other institutional investors own 80.54% of the company's stock.

About Nkarta

Nkarta, Inc is a clinical-stage biotechnology company specializing in the development of off-the-shelf natural killer (NK) cell therapies for the treatment of cancer. Leveraging proprietary activation and expansion technologies, Nkarta aims to harness the innate tumor-killing properties of NK cells while incorporating targeted immuno-engineering approaches to enhance safety, potency and persistence in patients. The company's platform supports both allogeneic cell manufacturing and genetic modifications to generate chimeric antigen receptor-expressing NK cell candidates designed to address a range of hematologic and solid tumors.

Nkarta's lead program, NKX019, is an anti-CD19 CAR-NK cell therapy in early-phase clinical trials for relapsed or refractory B-cell malignancies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source